Cancer/ ESMO2016/ R&D Cancer market commentary: 3 highlights from ESMO (Part 1) Andrew McConaghie AstraZeneca, breast, cancer, ESMO, Faslodex, kantar, Lynparza, Oncology, ovarian, pharma, treatment 0 Comment Commentary on key cancer data from ESMO by Stephanie Hawthorne Share X Cancer market commentary: 3 highlights from ESMO (Part 1) https://pharmaphorum.com/esmo-2016/cancer-market-commentary-3-highlights-esmo-conference-part-1/